Atinary Technologies and Snapdragon Chemistry partner to optimize drug development with AI

Atinary Technologies and Snapdragon Chemistry, a Cambrex company, have announced a strategic collaboration to integrate AI-driven process optimization technology with advanced pharmaceutical development capabilities, aiming to revolutionize drug development.

Atinary Technologies, a leading provider of AI-driven research and development (R&D) platforms, has entered into a strategic collaboration with Snapdragon Chemistry, a Cambrex company, to address complex drug development challenges. The partnership aims to integrate Atinary’s Self-Driving Labs™ (SDLabs™) technology with Snapdragon’s advanced laboratory and process development capabilities to enhance drug discovery and production.

Snapdragon Chemistry, known for its expertise in continuous flow process development and complex synthetic APIs, has successfully integrated its proprietary LabOS™ software platform with Atinary’s SDLabs™. This collaboration has enabled the development of a fully automated, AI-driven system for optimizing solid-phase oligonucleotide synthesis. Using Atinary’s AI platform, Snapdragon’s process optimization efforts have demonstrated up to an 18% increase in product yield and a 22% reduction in cost compared to traditional methods.

In the company’s press release, Dr. Hermann Tribukait, Co-Founder and CEO of Atinary, emphasized the importance of this collaboration in accelerating innovation in the pharmaceutical and biotechnology industries. “Our AI and data-driven solutions address complex chemistry and molecular discovery challenges faster than traditional methods,” he said, underscoring the transformative potential of this partnership.

Bringing significant advances to the pharmaceutical industry

Snapdragon’s advanced R&D infrastructure and ability to design self-contained reactors play a critical role in this collaboration. Dr. Eric Fang, General Manager of Snapdragon Chemistry, expressed his excitement about the partnership, highlighting the two companies’ shared vision to streamline drug development pipelines and enhance R&D portfolios through AI-driven technologies.

With a focus on improving the efficiency and reducing the cost of drug manufacturing, this collaboration between Atinary and Snapdragon Chemistry promises to bring significant advances to the pharmaceutical industry, benefiting both companies’ customers and accelerating the drug development process.

This partnership follows Atinary Technologies’ recent successes in material and molecular innovation and further expands the reach of its no-code AI platform across multiple sectors, including pharmaceuticals, biotech, chemicals and more.